KindlyMD (NASDAQ:NAKA) Sees Large Volume Increase - Should You Buy?

Key Points

• KindlyMD saw a significant increase in trading volume, with 9,944,238 shares traded on Thursday, marking a rise of 121% compared to the previous session.
• Maxim Group initiated coverage on KindlyMD with a buy rating and a price target of $8.00, while the stock currently has an average rating of "Buy" from analysts.
• The company reported a quarterly loss, with an EPS of ($0.34) and revenue of $0.41 million, indicating negative return on equity and net margin.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 9,944,238 shares changed hands during mid-day trading, an increase of 121% from the previous session's volume of 4,501,877 shares.The stock last traded at $1.43 and had previously closed at $1.43.

Analysts Set New Price Targets

Separately, Maxim Group started coverage on KindlyMD in a report on Wednesday, September 3rd. They set a "buy" rating and a $8.00 price objective on the stock. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, KindlyMD presently has a consensus rating of "Buy" and a consensus price target of $8.00.

KindlyMD Price Performance

The company has a market cap of $502.91 million, a price-to-earnings ratio of -1.55 and a beta of 34.05. The company's 50-day simple moving average is $8.04.

KindlyMD (NASDAQ:NAKA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $0.41 million during the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.